SAN DIEGO, June 30, 2026 /PRNewswire/ — At BIO 2026, EirGenix presented its comprehensive HER2-positive breast cancer biosimilar portfolio and highlighted its integrated one-stop contract development and manufacturing organization (CDMO) service platform. The company actively pursued U.S….
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
